TenNor Therapeutics has a unique multi-targeting drug conjugate technology platform, which serves as a competent source of innovative drug candidates for its development pipeline. The technology platform consists of three components: design, synthesis, and evaluation. The key know-how lies in the evaluation system, wherein a unique isogenic drug-resistant mutant panel is established to efficiently generate key data to guide through the design and optimization of the conjugated drug molecules, so as to ensure the most balanced multi-targeting activities and pharmacodynamic synergies. The isogenic drug-resistant strain panel is a proprietary technology of TenNor oriented by the target indications, which can rapidly generate key technical data and information of the conjugated molecules to verify the achievement of multi-targeting activities, balance of activities against different targets and the synergistic effect.